Lung Fluid Sensing Device to Guide Care After Heart Attack
Tests a lung fluid sensing device in adults with heart attack and weak heart function.
Plain-language title generated from the registry record
Registry title: Noninvasive Assessment of Pulmonary Fluid Levels by Remote Dielectric Sensing Technology to Improve Cardiac InsUfficieney During Ischemia-Reperfusion and Clinical Outcomes in MyocArdiaL Infarction
Key facts
- Where
- Kaifeng, Shanghai, and Zhengzhou, ChinaSee the 6 sites
Where in China
- Huaihe Hospital of Henan UniversityKaifeng, ChinaNo longer taking part
- Kaifeng Central HospitalKaifeng, ChinaNo longer taking part
- Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine ShanghaiShanghai, ChinaNo longer taking part
- Shanghai Tenth People's HospitalShanghai, ChinaNo longer taking part
- Songjiang Hospital Affiliated to Shanghai Jiao Tong University School of MedicineShanghai, ChinaNo longer taking part
- The First Affiliated Hospital of Zhengzhou UniversityZhengzhou, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai 10th People's Hospital
- Trial code
- NCT06671067
- Record updated
- 4 November 2024
- Original description
To explore whether a ReDS-guided strategy for AMI patients with cardiac insufficiency following coronary flow reperfusion is superior to routine care for improving outcomes.Read full original descriptionShow less
Noninvasive Assessment of Pulmonary Fluid Levels by Remote Dielectric Sensing (ReDS™) Technology to Improve Cardiac Insufficiency During Ischemia-reperfusion and Clinical Outcomes in Myocardial Infarction
To explore whether a ReDS-guided strategy for AMI patients with cardiac insufficiency following coronary flow reperfusion is superior to routine care for improving outcomes.
Inclusion: Patients were required to be aged ≥ 18 years and to be hospitalized for a primary diagnosis of AMI,; AMI patients accompanied by cardiac insufficiency following coronary revascularization, which is characterized by the symptoms and signs of fluid overload, regardless of left ventricular ejection fraction (LVEF), and have an N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration of ≥ 400 pg/L or a BNP concentration of ≥ 100 pg/L.
Exclusion: Patients with chronic obstructive pulmonary disease or other lung diseases that might confound ReDS values; Patients with a left ventricular assist device or undergoing cardiac transplantation; Patients with congenital heart malformations or intrathoracic mass that would affect right lung anatomy; Patients with end-stage renal disease on hemodialysis; Patient's physical characteristics that prevented the use of the ReDS system (height of <155 or >190 cm; body mass index of <22 or >39 kg/m2); Patients whose life expectancy less than 12 months due to noncardiac comorbidities; Patients who participate in another randomized studies.